Search for: [Abstract = "and pAVG was lower \-28.6, \-24.4, \-8.7, \-4.8 mmHg, respectively, p<0.05 for all\) as compared to baseline. In patients with impaired LV function n=34 \(30.4%, LVEF< 40%\) we observed significant improvement of LVEF \(median \+16%\) after 1 month \(p<0.05\) and this effect was stable up to 6 months after BAV. There was one severe AR after 12 months and patient was successfully treated with TAVI. Major complications occurred in 21 patients\: a\) intraprocedural death \(n=3\), b\) tamponade \(n=2\), c\) severe AR \(n=1\),d\) severe cardiac arrhythmias \(n=5\), e\) permanent pacemaker implantation \(n=1\), f\) need for red blood cells transfusion\: 1 unit in 3 patients, 2 units in 5 patients, 4 units in 4 patients, 5 units in 1 patient\(n=13\). Vascular access site complications \(VC\) occurred in 11 patients \(9.8%\). Peri\-procedural, in\-hospital, 1\-, 6\-, 12\-month mortality were 2.7%\; 8.9%\; 8.9 %\; 16.9%\; 22.3%, respectively. Inunivariate analysis females had higher prevalence of VC than males\(14.3% compared with 2.4%, p=0.04\). In multivariate logistic regression analysis, the only independent predictor of 12\-month all causemortality was STS \- HR \(95% CI\) 1.130 \(1.038 to 1.231\)\;p=0.05.In the second analysis of the 97 patients, 34 \(35.0%\) underwentstandalone BAV, 45 \(46.4%\) underwent BAV with coronary angiography and 18 \(18.6%\) BAV with PCI. Almost half of the patients who underwent BAV with PCI had a history of p"]

Number of results: 1